Diagnosis of Urinary Tract SymptonsBlaSTNCT04017000
Bladder Shaper Test
A study testing Bladder Shape Test and Calibration images in people with Diagnosis of Urinary Tract Symptons, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This study is comparing a novel method of Bladder shape measurements using ultrasound for diagnosis of lower urinary tract symptoms in comparison to traditional Urodynamic assessment. All participants will undergo the novel investigation followed by their usual Urodynamics. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Diagnosis of Urinary Tract Symptons
- What is being tested?
- Bladder Shape Test and Calibration images
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 156 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 2 Apr 2019to 31 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women referred for urodynamic evaluation of LUTS, including urinary storage symptoms, with or without incontinence.
- Women aged 18 years and over.
- Women willing and able to discontinue any current anticholinergic medication for a minimum period of 10 days prior to starting any study-related procedure.
- Women who understand and are willing and feel able to comply with the study protocol/procedures and who have provided written informed consent.
Who cannot join
- Current pregnancy
- Suspicion of pelvic malignancy
- Unable to consume 1000ml still water over 20 minutes
- Current urinary tract infection (UTI) (as assessed by urine dipstick and symptomatology. Patients with current UTI will be treated and further BlaST/Urodynamics appointments offered as appropriate. Women with cyclical urinary symptoms in association with menstrual cycle will be scheduled for BlaST and conventional Urodynamics at the same time each month, other patients will receive both tests usually within a month of each other, but never on the same day.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: BLAdder Shape Test: Medium-fill Cystometry and Trans-abdominal Assessment of Bladder Shape in Women With Overactive Bladder
This study is comparing a novel method of Bladder shape measurements using ultrasound for diagnosis of lower urinary tract symptoms in comparison to traditional Urodynamic assessment. All participants will undergo the novel investigation followed by their usual Urodynamics.
Read the detailed description
This study hypothesises that bladder shape changes associated with involuntary contractions of the detrusor muscle, might be detected using trans abdominal ultrasound, which could itself form the basis of a novel diagnostic test for detecting involuntary contractions associated with overactive bladder syndrome and urgency incontinence.
The detection of involuntary bladder contractions currently relies on invasive internal pressure measurement, commonly termed Urodynamics. This is an invasive test involving the placement of pressure measurement catheters, usually via the urethra into the bladder and via the anal canal into the rectum. In its normal healthy state, the bladder remains a contractile throughout filling and is compliant, meaning that there is minimal or zero increase in pressure as it fills. During Urodynamics, the bladder is filled artificially, using a pump, with water or contrast medium via a urethral catheter, whilst abdominal pressure is measured via a rectal catheter introduced anally. Differences between pressure measurements in the bladder and the abdomen are used to detect involuntary detrusor contractions; termed 'detrusor over activity when detected during Urodynamics. Patients often report Urodynamics as being uncomfortable and undignified, and the test carries a risk of introducing urinary tract infection. Furthermore, there are significant issues relating to the sensitivity of Urodynamics in the detection of abnormal bladder contractions in the context of Overactive Bladder.
Variations in bladder shape have been observed in association with detrusor over activity during video-Urodynamics, when fluoroscopic images are captured during filling with contrast medium. At one extreme, women with neuropathic overactive bladder have been observed to have tense, spherical or dome-shaped bladders with trabeculations 'fir tree' or 'Christmas tree' bladder. In women with normal detrusor muscle function, the bladder outline appears relaxed and a contractile, following the contours of the pelvis when assessed by cystography.
Although conventional Urodynamics has previously been regarded as the 'Gold Standard' in the assessment of lower urinary tract disorders, it is also well recognised as having issues of sensitivity, patient acceptability and cost. The test is commonly employed to diagnose and better understand the underlying pathophysiology of incontinence and is often deemed necessary, particularly prior to invasive forms of treatment. The requirement for urodynamic equipment, including its purchase, maintenance, associated training and size restricts its use to specialist hospital facilities, rendering it relatively inaccessible as a diagnostic tool. In addition to this patients have reported finding Urodynamics embarrassing and uncomfortable and with the inclusion of x-ray screening (video-cystometry) which is part of the procedure which aims to contemporaneously evaluate lower urinary tract structure and morphology, involves exposure to ionising radiation and is of unproven benefit. Therefore, there is a patient \& clinical need to objectively assess lower urinary tract function with less invasive, sensitive, reproducible and more widely available tests.
A pilot study will now be performed to establish the use of bladder shape testing as a new investigation for the assessment and diagnosis of lower urinary tract disorders. It is anticipated that this pilot will lead to the development of a new healthcare product that can be used in the primary care setting as an alternative to urodynamic assessment in the acute secondary care environment.
- Conditions
- Diagnosis of Urinary Tract Symptons
- Being tested
- Bladder Shape Test, Calibration images
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bladder Shape TestDiagnostic test
Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
Calibration imagesOther
Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
| Study group | Role | What they receive |
|---|---|---|
| BlaST study | Active comparator | Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.
The participants Urodynamic clinic will run according to routine care. Receives: Diagnostic Test: Bladder Shape Test |
| Calibration Sub Study | Other | Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.
Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.
Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change. Receives: Other: Calibration images |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment
Assessing recruitment rate for a larger study
Measured: At 12 months
Participants Completion Rate
Assessing drop out and completing patients to inform sample size for larger study
Measured: At 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2019
- Study start2 Apr 2019
- Primary completion31 Jan 2022
- Study completion31 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diagnosis of Urinary Tract SymptonsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 156 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- University of Sheffield
- Responsible party
- Sponsor
- Investigators
- Stephen Radley, Principal investigator, Sheffield Teaching Hospitals NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04017000
- Sponsor's protocol ID
- STH20318
- Acronym
- BlaST
- Status last verified
- Jun 2022
- First submitted
- 2 Jul 2019
- Last updated
- 22 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BLAdder Shape Test: Medium-fill Cystometry and Trans-abdominal Assessment of Bladder Shape in Women With Overactive Bladder
- ClinicalTrials.gov ID
- NCT04017000
- Acronym / sponsor ID
- BlaST / STH20318
- Conditions
- Diagnosis of Urinary Tract Symptons
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 156 participants (actual)
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation TrustUniversity, hospital or other
- Collaborators
- University of Sheffield
- Study start
- 2 Apr 2019 (actual)
- Primary completion
- 31 Jan 2022 (actual)
- Study completion
- 31 Jan 2022 (actual)
- First posted
- 12 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is comparing a novel method of Bladder shape measurements using ultrasound for diagnosis of lower urinary tract symptoms in comparison to traditional Urodynamic assessment. All participants will undergo the novel investigation followed by their usual Urodynamics.
Detailed description
This study hypothesises that bladder shape changes associated with involuntary contractions of the detrusor muscle, might be detected using trans abdominal ultrasound, which could itself form the basis of a novel diagnostic test for detecting involuntary contractions associated with overactive bladder syndrome and urgency incontinence.
The detection of involuntary bladder contractions currently relies on invasive internal pressure measurement, commonly termed Urodynamics. This is an invasive test involving the placement of pressure measurement catheters, usually via the urethra into the bladder and via the anal canal into the rectum. In its normal healthy state, the bladder remains a contractile throughout filling and is compliant, meaning that there is minimal or zero increase in pressure as it fills. During Urodynamics, the bladder is filled artificially, using a pump, with water or contrast medium via a urethral catheter, whilst abdominal pressure is measured via a rectal catheter introduced anally. Differences between pressure measurements in the bladder and the abdomen are used to detect involuntary detrusor contractions; termed 'detrusor over activity when detected during Urodynamics. Patients often report Urodynamics as being uncomfortable and undignified, and the test carries a risk of introducing urinary tract infection. Furthermore, there are significant issues relating to the sensitivity of Urodynamics in the detection of abnormal bladder contractions in the context of Overactive Bladder.
Variations in bladder shape have been observed in association with detrusor over activity during video-Urodynamics, when fluoroscopic images are captured during filling with contrast medium. At one extreme, women with neuropathic overactive bladder have been observed to have tense, spherical or dome-shaped bladders with trabeculations 'fir tree' or 'Christmas tree' bladder. In women with normal detrusor muscle function, the bladder outline appears relaxed and a contractile, following the contours of the pelvis when assessed by cystography.
Although conventional Urodynamics has previously been regarded as the 'Gold Standard' in the assessment of lower urinary tract disorders, it is also well recognised as having issues of sensitivity, patient acceptability and cost. The test is commonly employed to diagnose and better understand the underlying pathophysiology of incontinence and is often deemed necessary, particularly prior to invasive forms of treatment. The requirement for urodynamic equipment, including its purchase, maintenance, associated training and size restricts its use to specialist hospital facilities, rendering it relatively inaccessible as a diagnostic tool. In addition to this patients have reported finding Urodynamics embarrassing and uncomfortable and with the inclusion of x-ray screening (video-cystometry) which is part of the procedure which aims to contemporaneously evaluate lower urinary tract structure and morphology, involves exposure to ionising radiation and is of unproven benefit. Therefore, there is a patient \& clinical need to objectively assess lower urinary tract function with less invasive, sensitive, reproducible and more widely available tests.
A pilot study will now be performed to establish the use of bladder shape testing as a new investigation for the assessment and diagnosis of lower urinary tract disorders. It is anticipated that this pilot will lead to the development of a new healthcare product that can be used in the primary care setting as an alternative to urodynamic assessment in the acute secondary care environment.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BlaST study | Active comparator | Diagnostic Test: Bladder Shape TestPatients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding. The participants Urodynamic clinic will run according to routine care. |
| Calibration Sub Study | Other | Other: Calibration imagesAny patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study. Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound. Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Women referred for urodynamic evaluation of LUTS, including urinary storage symptoms, with or without incontinence.
- Women aged 18 years and over.
- Women willing and able to discontinue any current anticholinergic medication for a minimum period of 10 days prior to starting any study-related procedure.
- Women who understand and are willing and feel able to comply with the study protocol/procedures and who have provided written informed consent.
Key exclusion criteria (4 listed)
- Current pregnancy
- Suspicion of pelvic malignancy
- Unable to consume 1000ml still water over 20 minutes
- Current urinary tract infection (UTI) (as assessed by urine dipstick and symptomatology. Patients with current UTI will be treated and further BlaST/Urodynamics appointments offered as appropriate. Women with cyclical urinary symptoms in association with menstrual cycle will be scheduled for BlaST and conventional Urodynamics at the same time each month, other patients will receive both tests usually within a month of each other, but never on the same day.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bladder Shape TestCapturing images of bladder under natural filling conditions images are analysed at a later date for shape change. | Diagnostic test | BlaST study |
| Calibration imagesCapturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology. | Other | Calibration Sub Study |
Primary outcome
Recruitment
Time frame: At 12 months
Assessing recruitment rate for a larger study
Participants Completion Rate
Time frame: At 12 months
Assessing drop out and completing patients to inform sample size for larger study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2022.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephen Radley principal investigator
Sheffield Teaching Hospitals NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bladder Shape Test and Calibration images in people with Diagnosis of Urinary Tract Symptons, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment (time frame: At 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2022.